Similar articles

• Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

  James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MKB, Ritchie AWS, Russell JM, Strebel RT, Thalmann GN, Mason MD, Sydes MR. James ND, et al. Eur Urol. 2015 Jun;67(6):1028-1038. doi: 10.1016/j.eururo.2014.09.032. Epub 2014 Oct 6. Eur Urol. 2015. PMID: 25301760 Clinical Trial.
• Observed Advantages of the STAMPEDE Study Design.

  Scher HI. Scher HI. Eur Urol. 2015 Jun;67(6):1039-1041. doi: 10.1016/j.eururo.2014.12.004. Epub 2014 Dec 25. Eur Urol. 2015. PMID: 25544634 No abstract available.
• Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.

  Davda R, Hughes S, Jones R, Crabb SJ, Troup J, Payne H. Davda R, et al. Clin Oncol (R Coll Radiol). 2016 Jun;28(6):376-85. doi: 10.1016/j.clon.2016.01.006. Epub 2016 Feb 11. Clin Oncol (R Coll Radiol). 2016. PMID: 26874654 Afrikaans, English.
• Chemotherapy for metastatic castrate-sensitive prostate cancer.

  Miller RE, Sweeney CJ. Miller RE, et al. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):139-44. doi: 10.1038/pcan.2016.10. Epub 2016 Mar 15. Prostate Cancer Prostatic Dis. 2016. PMID: 26976365 Review.
• Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world.

  Thompson AL, Sarmah P, Beresford MJ, Jefferies ER. Thompson AL, et al. BJU Int. 2017 Dec;120(6):751-754. doi: 10.1111/bju.13990. Epub 2017 Sep 5. BJU Int. 2017. PMID: 28834013 Review. No abstract available.